May 7 2015
Myriad Genetics, Inc. announced it will present three studies that demonstrate the value of the Prolaris test for physicians and their patients at the 2015 American Urological Association (AUA) Annual Meeting being held May 15 to 19 in New Orleans, La.
Key presentations will showcase a new “active surveillance threshold” for men with localized prostate cancer based on the Prolaris test score, and the final results from PROCEDE 1000, which is the largest prospective clinical utility study to measure the impact of the Prolaris test on the treatment of men with localized prostate cancer. Abstracts of the Company’s presentations will be available at: www.aua2015.org/abstracts/.
“We are very excited about our presentations at AUA. The results show how the Prolaris test is helping physicians assess the aggressiveness of prostate cancer and more importantly, personalize treatment plans for their patients to achieve better care,” said Michael Brawer, M.D., vice president of Medical Affairs, Myriad. “The addition of a validated active surveillance threshold based upon disease-specific mortality provides a unique and definitive tool for physicians and patients to personalize treatment plans.”
The data being highlighted at AUA 2015 include:
Podium Presentation
Title: Significant reduction in therapeutic burden from use of CCP test in treatment decisions among newly diagnosed prostate cancer patients in a large prospective registry (PD32-11).
Podium Presenter: Neal Shore, M.D.
Date: Sunday, May 17, 3:30 p.m. to 5:30 p.m. CT
Room: 215-216
Poster Presentations
Title: Patient AUA risk classification based on combined clinical cell cycle risk (CCR) score (MP1-08).
Poster Presenter: Jack Cuzick, Ph.D.
Date: Friday, May 15, 10:30 a.m. to 12:30 p.m. CT
Room: 220-221
Title: Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer (MP1-10).
Poster Presenter: Jack Cuzick, Ph.D.
Date: Friday, May 15, 10:30 a.m. to 12:30 p.m. CT
Room: 220-221
About Prolaris®
Prolaris is a novel 46-gene RNA-expression test that directly measures tumor cell growth characteristics for stratifying the risk of disease-specific mortality in prostate cancer patients. Prolaris provides a quantitative measure of the RNA expression levels of genes involved in the progression of tumor growth. Low gene expression is associated with a low risk of disease-specific mortality in men who may be candidates for active surveillance and high gene expression is associated with a higher risk of disease-specific mortality in patients who may benefit from additional therapy. For more information visit: www.prolaris.com.
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis